Eli Lilly and Company lands in Boston for HLTH healthcare innovation think tank

Eli Lilly and Company sent its Gulfstream G500, registration N307EL, from Indianapolis International Airport to Boston Logan International Airport on May 11, 2026. The jet lifted off at 3:30 p.m. EDT, slicing through the skies at a maximum altitude of 45,025 feet and ground speeds topping 561 knots, before alighting at 5:25 p.m. after a brisk 1 hour and 54 minutes aloft.

The arrival synced neatly with HLTH's afternoon Think Tank in Boston, a closed-door forum probing the shift from direct-to-consumer health innovations to broader system adoption. Eli Lilly and Company brass, including Vice President of Global Pain John Markman and AVP of Connected Medicine Kirk Keaffaber, joined panels alongside peers from Moderna, Sanofi, and Takeda to dissect commercialization hurdles and value creation in digital health, per the event agenda.

Such jaunts underscore Eli Lilly and Company's restless itinerary, shuttling between its Indianapolis base and power centers like New York, Seattle, and Toronto in recent days—chasing deals in the GLP-1 surge and oncology frontiers, where a Boston biotech's $1.3 billion pact hints at the stakes.